Texas Capital Bancshares Inc TX Reduces Stock Position in Johnson & Johnson $JNJ

Texas Capital Bancshares Inc TX lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,329 shares of the company’s stock after selling 194 shares during the quarter. Texas Capital Bancshares Inc TX’s holdings in Johnson & Johnson were worth $718,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Elios Financial Group Inc. grew its holdings in Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock worth $746,000 after acquiring an additional 66 shares during the period. Atlantic Family Wealth LLC boosted its position in Johnson & Johnson by 4.4% in the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock worth $266,000 after purchasing an additional 67 shares in the last quarter. MBA Advisors LLC grew its stake in shares of Johnson & Johnson by 1.2% during the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock worth $921,000 after purchasing an additional 68 shares during the period. Sovereign Financial Group Inc. increased its holdings in shares of Johnson & Johnson by 1.8% during the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock valued at $651,000 after purchasing an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc lifted its stake in shares of Johnson & Johnson by 1.5% in the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock valued at $767,000 after purchasing an additional 69 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on JNJ. Barclays raised their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Benchmark upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. UBS Group lifted their price target on Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a research note on Thursday, July 17th. Finally, Guggenheim restated a “neutral” rating and issued a $167.00 price target (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Nine research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $174.50.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $176.26 on Tuesday. The business has a 50 day simple moving average of $161.70 and a two-hundred day simple moving average of $158.60. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $177.57. The stock has a market capitalization of $424.49 billion, a P/E ratio of 18.85, a PEG ratio of 2.25 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The business had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter in the prior year, the firm earned $2.82 earnings per share. The business’s revenue was up 5.8% compared to the same quarter last year. As a group, analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.